地域医療学センター

村松 慎一

ムラマツ シンイチ  (Shin-ichi Muramatsu)

基本情報

所属
自治医科大学 医学部 客員教授
学位
医学博士(自治医科大学)

ORCID ID
 https://orcid.org/0000-0002-3185-7790
J-GLOBAL ID
200901074911542236
researchmap会員ID
1000063389

神経疾患の遺伝子治療を開発しています。

受賞

 4

論文

 364
  • Naotaka Izuo, Daiki Ikejima, Kyosuke Uno, Takashi Asano, Shin-Ichi Muramatsu, Atsumi Nitta
    Biochemical and biophysical research communications 736 150435-150435 2024年7月22日  
    Shati/Nat8l was identified as an upregulated molecule in the nucleus accumbens (NAc) of mice following repeated methamphetamine administration. Region-specific roles of this molecule are associated with psychiatric disorders. In the present study, we examined the importance of Shati/Nat8l in the hippocampus because of its high expression in this region. Mice with a hippocampus-specific knockdown of Shati/Nat8l (hippocampal Shati-cKD) were prepared by the microinjection of adeno-associated virus (AAV) vectors carrying Cre into the hippocampus of Shati/Nat8lflox/flox mice, and their phenotypes were investigated. Drastic reduction in the expression and function of Shati/Nat8l in the hippocampus was observed in Shati-cKD mice. These mice exhibited cognitive dysfunction in behavioral experiments and impaired the electrophysiological response to the stimuli, which elicits long-term potentiation. Shati/Nat8l in the hippocampus is suggested to possibly play an important role in synaptic plasticity to maintain cognitive function. This molecule could be a therapeutic target for hippocampus-related disorders such as dementia.
  • Kareem Abdou, Masanori Nomoto, Mohamed H. Aly, Ahmed Z. Ibrahim, Kiriko Choko, Reiko Okubo-Suzuki, Shin-ichi Muramatsu, Kaoru Inokuchi
    Nature Communications 2024年6月  査読有り
  • Shin-Ichi Muramatsu
    International journal of cardiology 400 131704-131704 2024年4月1日  
  • Yoshiaki Tanaka, Rina Takagi, Shingen Mitou, Machiko Shimmura, Tetsuya Hasegawa, Jota Amarume, Masami Shinohara, Yasushi Kageyama, Tomohiko Sasase, Takeshi Ohta, Shin-Ichi Muramatsu, Akihiro Kakehashi, Toshikatsu Kaburaki
    Biological & pharmaceutical bulletin 2024年3月1日  
    Diabetic retinopathy (DR) can cause visual impairment and blindness, and the increasing global prevalence of diabetes underscores the need for effective therapies to prevent and treat DR. Therefore, this study aimed to evaluate the protective effect of pemafibrate treatment against DR, using a Spontaneously Diabetic Torii (SDT) fatty rat model of obese type 2 diabetes. SDT fatty rats were fed either a diet supplemented with pemafibrate (0.3 mg/kg/day) for 16 weeks, starting at 8 weeks of age (Pf SDT fatty: study group), or normal chow (SDT fatty: controls). Normal chow was provided to Sprague-Dawley (SD) rats (SD: normal controls). Electroretinography (ERG) was performed at 8 and 24 weeks of age to evaluate the retinal neural function. After sacrifice, retinal thickness, number of retinal folds, and choroidal thickness were evaluated, and immunostaining was performed for aquaporin-4 (AQP4). No significant differences were noted in food consumption, body weight, or blood glucose level after pemafibrate administration. Triglyceride levels were reduced, and high-density lipoprotein cholesterol levels were increased. Extension of oscillatory potential (OP)1 and OP3 waves on ERG was suppressed in the Pf SDT fatty group. Retinal thickness at 1,500 microns from the optic disc improved in the Pf SDT fatty group. No significant improvements were noted in choroidal thickness or number of retinal folds. Quantitative analyses showed that AQP4-positive regions in the retinas were significantly larger in the Pf SDT fatty group than in the SDT fatty group. The findings suggest that pemafibrate treatment can exert protective effects against DR.
  • Hajime Miyanishi, Shiori Suga, Kazuyuki Sumi, Miho Takakuwa, Naotaka Izuo, Takashi Asano, Shin-Ichi Muramatsu, Atsumi Nitta
    eNeuro 10(10) 2023年10月  
    Depression is a frequent and serious illness, and stress is considered the main risk factor for its onset. First-line antidepressants increase serotonin (5-hydroxytryptamine; 5-HT) levels in the brain. We previously reported that an N-acetyltransferase, Shati/Nat8l, is upregulated in the dorsal striatum (dSTR) of stress-susceptible mice exposed to repeated social defeat stress (RSDS) and that dSTR Shati/Nat8l overexpression in mice (dSTR-Shati OE) induces stress vulnerability and local reduction in 5-HT content. Male mice were used in this study, and we found that dSTR 5-HT content decreased in stress-susceptible but not in resilient mice. Moreover, vulnerability to stress in dSTR-Shati OE mice was suppressed by the activation of serotonergic neurons projecting from the dorsal raphe nucleus (dRN) to the dSTR, followed by upregulation of 5-HT content in the dSTR using designer receptors exclusively activated by designer drugs (DREADD). We evaluated the role of GABA in modulating the serotonergic system in the dRN. Stress-susceptible after RSDS and dSTR-Shati OE mice exhibited an increase in dRN GABA content. Furthermore, dRN GABA content was correlated with stress sensitivity. We found that the blockade of GABA signaling in the dRN suppressed stress susceptibility in dSTR-Shati OE mice. In conclusion, we propose that dSTR 5-HT and dRN GABA, controlled by striatal Shati/Nat8l via the dSTR-dRN neuronal circuitry, critically regulate stress sensitivity. Our study provides insights into the neural processes that underlie stress and suggests that dSTR Shati/Nat8l could be a novel therapeutic target for drugs against depression, allowing direct control of the dRN serotonergic system.

MISC

 214

共同研究・競争的資金等の研究課題

 17